NEW YORK (GenomeWeb News) – MDxHealth today announced New York has certified the company's prostate cancer test, allowing MDxHealth to offer the test to residents in the state.

The company can now offer the ConfirmMDx test in all 50 states in the US. The epigenetics-based test, which was launched in May 2012, uses tissue obtained from a previous negative prostate biopsy to differentiate patients with true negative results from those who are at high risk for missed cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: gene regulation changes linked to human brain evolution, and more.

The New York Stem Cell Foundation's Initiative on Women in Science and Engineering working group presents seven strategies to promote gender equality in the sciences.

Researchers link a genetic variation to the ability to quickly process arsenic in people living in the Andes Mountains.

A small portion of pregnant women who've undergone non-invasive prenatal testing have found out from the test that they have cancer.